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Background: Hepatitis B (HB) is an important disease worldwide. Almost 350 million people are positive for
Hepatitis B virus surface antigen (HBsAg), and one-third of them live in China. According to a nation-wide
serosurvey in China in 2006, the prevalence of HBsAg was higher in Northwest China than in other areas. However,
the epidemic HBV strains in this area are poorly studied.
Results: In this study, 242 complete hepatitis B virus (HBV) genome sequences were obtained from HBV
asymptomatic carriers in major cities of Northwest China. The 242 HBV sequences clustered into genotypes B, C
and D. Through comparison of the genotype consensus sequences, 158 genotype-dependent positions were
observed in P, S and X ORFs. Clinically relevant mutation screening in this study revealed that no HBV antiviral drug
resistance mutations were observed and the vaccination failure mutations were heavily underrepresented.
Conclusions: The role of genotype D strains in HBV prevalence should not be ignored in Northwest China. Due to
low prevalence of vaccination failure mutations, it can be inferred that the genotype B, C and D strains in
Northwest China may have less likelihood of vaccine escape.
Keywords: Hepatitis B virus, Consensus sequences, Clinically relevant mutationsBackground
Hepatitis B virus (HBV) infection is an important global
disease. It is estimated that almost 350 million people
are chronically infected, and the virus causes approxi-
mately 1 million deaths annually [1,2]. A nation-wide sero-
survey in 2006 in China showed that in the population
aged 1–59 years old, the prevalence of HBsAg was 7.2%
overall and varied in different areas [3]. In Northwestern
China, due to poor HBV knowledge, delayed vaccine in-
oculation or other unknown reasons, the HBV prevalence
is over 8.3% according to our study (unpublished), which
is much higher than in other areas. However, the epidemic
HBV strains in this area of China are poorly studied. For
example, among the 1535 complete Chinese HBV ge-
nomes published in the NCBI database, only 18 (1.17%)
were isolated in Northwest China. Therefore, to gain in-
sights into HBV prevalence in this highly epidemic area,* Correspondence: zhjshao@hotmail.com; yanyping@fmmu.edu.cn
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unless otherwise stated.242 complete HBV genome sequences isolated from this
region represented a genomic background for hepatitis
B virus, and this genomic background may provide an
important reference for studies of HBV evolution or for
further clinical studies. To our knowledge, this is the
first comprehensive description of the HBV genomic
background in this highly epidemic area of China.
Methods
Study subjects
From September 2006 to August 2012, 285,858 residents
undergoing a physical examination at the physical exam-
ination department of the local centers for disease pre-
vention and control were enrolled into this study from
major cities in Northwest China, i.e., Lanzhou City of
Gansu Province, Xi’an City of Shaanxi Province, Xining
City of Qinghai Province, Urumuqi City of the Xinjiang
Autonomous Region and Yinchuan City of the Ningxia
Autonomous Region. HBV serologic markers were tested
using commercially available enzyme-linked immunosorb-
ent assay kits (Abbott Laboratories, USA; Beijing Wantai
Co., Ltd, Beijing). Information about HB-related medicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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viral load was measured with qualitative assays (Roche
Ltd., Switzerland). Only patients positive for HBsAg,
having no HB-related medical history or typical clinical
symptoms, and with HBV DNA ≥ 105 IU/ml were en-
rolled. Approval was obtained from the local and Fourth
Military Medical University institutional ethics committee
before the study, and informed consent was obtained from
each individual. All serum samples were collected and
stored at −80°C before use.
Complete HBV genome sequencing
HBV DNA was extracted from 200 μL serum samples
using DNA/RNA extraction kits (Beijing Tiangen Co., Ltd,
Beijing). HBV DNA genomes were obtained by separately
amplifying three HBV segments: segment I (nt 56–756),
primers 5’-CTGCTGGTGGCTCCAGTT-3’ (sense primer,
nt 56–73) and 5’-CAATACCACATCATCCAT-3’ (anti-
sense primer, nt 756–739); segment II (nt 736–1889),
primers 5’-TATATGGATGATGTGGTATTGGG-3’ (sense
primer, nt 736–758) and 5’-ACCCAAGGCACAGC
TTGG-3’ (anti-sense primer, nt 1889–1872); and segment
III (nt 1806–195), primers 5’-CCAGCACCATGCAC
TTTTT-3’ (sense primer, nt 1806–1824) and 5’-CGAG
CAGGGGTCCTAGGA-3’ (anti-sense primer, nt 195–
177). PCR procedures were set as previously described
[4]. For each sample, three groups of PCR products
were cloned into the pCR4-TOPO vector (Invitrogen,
Shanghai), which was used to transform Top10 electro-
competent Escherichia coli cells (Invitrogen, Shanghai)
by electroporation. Colonies were screened using M13
universal primers. M13 PCR products of the correct size
were sequenced [5]. Furthermore, for each sample, the
three acquired sequences were analyzed and integrated
with Codoncode Aligner Software (version 4.0.3) into a
complete HBV genome.
Molecular evolutionary analyses
All 242 HBV sequences generated in this study were
manually edited by visual inspection and multiply aligned
with reference HBV sequences (GenBank accession num-
ber: Genotype A: AY233274; Genotype B: AB246341;
Genotype C: AB111946; Genotype D: EU594396; Geno-
type E: AB032431; Genotype F: EU670262; Genotype
G: AF160501) using Bioedit software (version 7.0). A
phylogenetic tree was constructed using the UPGMA
method. The reliability of the pairwise comparison and
phylogenetic tree analysis was assessed by bootstrap re-
sampling with 1000 replicates. Phylogenetic and molecular
evolutionary analyses were conducted using MEGA
(version 5.05) [6]. Consensus sequences were constructed
using the Mutation Master Server (http://cagt.bu.
edu/page/MutationMaster_about) [7]. Consensus se-
quences of different genotypes were compared todetermine genotype-dependent nucleotide positions
among different genotypes. Clinically relevant mutations
were also analyzed, as guided by previous clinical studies.
Statistical comparisons
Significant differences among different genotypes were
calculated using the χ2 test, Fisher’s exact probability
test and Student’s t-test where applicable. Two-tailed
P values ≥ 0.05 were considered statistically significant.
The R Project software version 2.14.2 was utilized for
statistical calculations.
GenBank accession number





Among 2293 HBsAg-positive patients without HB-related
medical history, 330 were identified with HBV ≥105 IU/ml,
and all patients were positive for Hepatitis B Virus E anti-
gen (HBeAg). Serum samples from these 330 patients
were subjected to amplification of the full-length HBV
genome, and 242 full-length HBV genomes were finally
obtained (Figure 1). Sixty-seven full-length HBV genomes
were obtained from the patients of Lanzhou, 27 from
Urumuqi, 78 from Xi’an, 56 from Xining, and 14 from
Yinchuan (Table 1). There was no significant difference
in the age, M/F ratio or clinical data with respect to case
locations.
HBV genotypes and serotypes
Phylogenetic analysis with GenBank reference sequences
indicated three distinct clusters, corresponding to the
HBV genotypes B, C and D (Figure 2). Among the 242
sequences generated in this study, genotype C (59.92%,
145/242) was the most frequently observed, followed by
genotype D (22.31%, 54/242) and genotype B (17.77%,
43/242). The relationship between case locations and ge-
notypes is displayed in Table 2.
In serotype analysis, the amino acids in the viral sur-
face gene were checked in the manner of previous stud-
ies to determine the serotype of each strain. As a result,
subtype adrq- (122 K + 127P + 134 F + 159 V + 160R +
177A +178P), adrq + (122 K + 127P + 134 F + 159A +
160R + 177 V +178P), adw2 (122 K + 127P + 134 F +
159A + 160 K + 177 V +178P), adw4q- (122 K + 127 L +
134 F + 159A + 160 K + 177 V +178P), ayr (122R + 127P +
134 F + 159A + 160R + 177 V +178P), ayw1 (122R +
127P + 134 F + 159A + 160 K + 177 V +178P), ayw2
(122R + 127P + 134Y + 159G + 160 K + 177 V +178P)
and ayw3 (122R + 127 T + 134 F + 159G + 160 K + 177
V +178P) were observed in these sequences. Subtype
Figure 1 The processes of case enrollment and complete HBV genome amplification.
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served, followed by subtype ayw2 (23.97%, 58/242) and
adw2 (16.12%, 39/242). In addition, there was no signifi-
cant difference in the distribution of HBV serotypes
with respect to genotypes (Table 3) [8].
Genotype consensus sequences
Through comparison of the three genotype consensus
sequences, 158 amino acid positions were found to be
significantly different among the consensus sequences.
Among these 158 identified genotype-dependent positions,Table 1 Demographic and clinical information for the patient
City No. of cases Age, yr (mean ± sd)
Lanzhou 67 29.63 ± 13.78
Urumuqi 27 28.74 ± 13.75
Xi’an 78 28.52 ± 12.88
Xining 56 30.05 ± 14.59
Yinchuan 14 32.29 ± 15.79
Total 242 28.74 ± 13.1496 (60.76%) were located in the P ORF, 47 (29.75%) in
the S ORF and 15 (9.49%) in the X ORF. No positions
were found in the C ORF (Figure 3A).
In the P ORF, 46 out of 96 (47.92%) genotype-
dependent positions were located in the spacer region,
followed by 28 (29.17%) in reverse transcriptase, 15
(15.63%) in terminal proteins and 7 (7.29%) in RNase H.
In the S ORF, 23 out of 47 (48.93%) genotype-dependent
positions were located in the S region, followed by 11
(23.40%) in the preS1 region and 13 (28.26%) in the preS2
region. In the X ORF, 11 out of 15 (73.33%) genotype-s in this study
M/F ratio ALT (U/L) AST (U/L)
42/25 42.65 ± 36.37 34.27 ± 25.70
10/17 48.79 ± 56.16 43.21 ± 59.04
40/38 43.81 ± 41.12 39.33 ± 40.91
29/27 42.77 ± 33.34 38.63 ± 21.74
8/6 29.00 ± 19.29 24.15 ± 12.22
132/110 43.89 ± 46.93 39.36 ± 45.42
Figure 2 Phylogenetic tree of the complete HBV genomes in this study generated by the UPGMA method. The reliability of pairwise
comparison and phylogenetic tree analysis was assessed by bootstrap resampling with 1000 replicates. The reference sequences of different
genotypes were retrieved from GenBank. The accession number was as follows: Genotype A: AY233274; Genotype B: AB246341; Genotype C:
AB111946; Genotype D: EU594396; Genotype E: AB032431; Genotype F: EU670262; Genotype G: AF160501.
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(first 50 amino acids), while only 4 (36.36%) were located
in the C-terminal region. Interestingly, in 112 of the 158
(70.89%) positions, the genotype B consensus sequence
showed differences from the other consensus sequences of
genotypes C and D, while the latter two were identical to
each other. This finding agreed with the higher divergence
between genotypes B and C/D (Figure 3B).
Clinically relevant mutations
To investigate the biological and clinical characteristics




Genotype B Genotype C Genotype D
Xi’an 78 23 52 3
Lanzhou 67 6 47 14
Yinchuan 14 0 12 2
Urumuqi 27 10 16 1
Xining 56 4 18 34
Total 242 43 145 54screened for clinically relevant mutations that were re-
ported in previous studies. In the P ORF, all sequences
were screened for mutations that were reported in pre-
vious studies to be associated with drug resistance:
rtL80V/I, rtL180M and rtM204V/I mutations, associ-
ated with LMV resistance; rtA181T and rtN236T muta-
tions, associated with ADV resistance; rtS184G, rtS202I
and rtM250V mutations, associated with ETV resistance;
the rtA194T mutation, associated with TDF resistance;
and the rtM204I mutation, associated with LdT resistance
[9,10]. However, none of these mutations were observed
in the present study.
In the S ORF, preS1 deletion mutations were detected in
16 sequences, and preS2 deletion mutations were detected
in 5 sequences. In addition, G129H/R mutations, which
have been suggested to be associated with low antibody
adherence, were found in the S region in eight sequences
[11]. G145R mutations, which were reported to be respon-
sible for vaccination failure, were found in five sequences.
Furthermore, in the α determinant, which is vital to HBV
antigenicity, mutations were also found in aa126, aa127,
aa130, aa131, aa134 and aa143 (Table 4).
The distribution of clinically relevant mutations in dif-
ferent genotypes was compared and is shown in Table 4.
Table 3 Relationship between complete HBV genome genotypes and serotypes
Genotype adr adw ayr ayw Total
adrq- adrq+ adw2 adw4 ayr ayw1 ayw2 ayw3
B 0 28 3 1 0 1 10 0 43
C 0 84 25 0 1 1 33 1 145
D 1 25 11 1 1 0 15 0 54
Total 1 137 39 2 2 2 58 1 242
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significantly different distribution among different geno-
types. Genotype D sequences were shown to have signifi-
cantly higher frequencies of preS1 deletion mutation.
Discussion
HBV infection is an epidemic in China. In Northwest
China, the prevalence of HBV infection is much higher
compared to other areas. In previous HBV studies in
Northwest China, phylogenetic analysis of the HBV S
region was employed to reveal the HBV genotypes [12].
However, the complete characteristics of epidemic HBV
strains have not been well studied, especially in those
strains in asymptomatic carriers. In this study, 242
complete HBV genome sequences were isolated from
asymptomatic carriers who underwent physical exami-
nations in the local centers for disease prevention and
control. Based on these sequences, consensus sequences
of genotypes B, C and D were determined and com-
pared with each other, and moreover, all the sequences
were screened for clinically relevant mutations. This
study, which presents the HBV genomic background of
early stage infection, will contribute to the establish-
ment of a reliable virus evolution history and provide
vital genomic baseline references for further clinical
studies.
In China, HBV genotypes B and C are suggested to be
the major genotypes in the population [13]. Since the
time Genotype D was first reported by Fan J et al. in the
Qinghai-Tibet Plateau in 1997, it has never been consid-
ered a major genotype in China [5,14]. However, in this
study, 54 of 242 (22.31%) HBV sequences were identified
as genotype D in Northwest China, which was higher
than expected. It can be inferred that genotype D may
play a more important role in HBV prevalence in western
China than previously expected.
The HBV genotype consensus sequence is important
in establishing an HBV genotype sequence motif and
inferring the genotype-dependent function of various
HBV domains. Mutation Master is a reliable server that
rapidly provides a visual display of consensus sequences
and genetic variability, using multiple sequence align-
ments [7]. In this study, Mutation Master Server was used
to analyze HBV sequences of different genotypes for con-
sensus sequences and genetic variability. By comparingdifferent genotype consensus sequences, we found that
most of the genotype-dependent variability was concen-
trated in the spacer region, which has not previously
been reported.
The P ORF and S ORF are the most important for the
prevention and therapy of HBV infection. In the P ORF,
28 genotype-dependent positions were detected in the
reverse transcriptase region, where there is a functional
domain in which reverse transcription and synthesis of
the second DNA strand occurs. Positions within this
region may be influenced and selected during antiviral
treatment by using nucleoside/nucleotide analogs, such
as lamivudine [10]. The presence of HBV genotype-
dependent variability in this therapeutic target region
suggests the role of clinical treatment selection in the
evolution of different HBV genotypes. In clinically rele-
vant mutation screening analysis, no HBV antiviral
drug resistance mutations were observed, which was
consistent with a similar HBV genetic diversity study
conducted in American blood donors [15]. Drug-
resistant HBV variants may be inefficient in transmis-
sion and/or establishment of a chronic infection or may
be underrepresented in the pool of HBV that is actively
transmitted by sexual or parenteral routes [16].
In the S region, 23 genotype-dependent positions were
detected, and 9 of these positions were located in the
major hydrophilic region. The small S protein is encoded
by the S region and is a major component of the viral
envelope that plays an important role in the host im-
mune response. The major hydrophilic region encom-
passes aa101-aa160 of the S protein and is exposed on
the surface to both virions and subviral particles. This
region is highly immunogenic and is potentially under
the selective pressure of the immune system [17]. The
presence of HBV genotype variability in this immune-
dominant region suggests the role of immune selection
in the evolution of different HBV genotypes. Deletion
mutations in preS regions were much less prevalent
(6.61%) compared to previously reported results in
Chinese chronic HBV infections and HCC (20%) [18,19].
This observation is consistent with these mutations lead-
ing to impaired virus particle secretion and thus being
negatively selected during the transmission of HBV. Ac-
cording to a similar study of HBV genetic diversity in
American blood donors, the prevalence of the well-known
Figure 3 Mapping of genotype-dependent positions. (A) Locations of genotype-dependent positions in S, P and X ORFs. (B) Amino acid
changes in the genotype-dependent positions. The genotype consensus sequences for genotype-dependent position comparisons were
determined using the Mutation Master Server online, using an input of the complete HBV genotype B-D sequences as generated in this study.
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Table 4 List of clinically relevant mutations detected in
the S ORF of the HBV complete genome sequences
acquired in this study
Genotype B Genotype C Genotype D Total
number
No of sequences 43 145 54 242
preS1 deletion
mutation**
0 5 11 16
preS2 deletion
mutation
1 4 0 5
G129H/R 1 5 2 8
G145R 1 4 0 5
T126A/S 1 1 1 3
P127T 0 4 2 6
G130R 1 2 0 3
T131P 2 5 2 9
M134Y 11 31 14 56
S143T/L 8 20 11 39
Mutations whose distributions varied significantly in different genotypes are
indicated with “**” (P < 0.01).
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lope protein was as high as 22% [15]. However, in contrast
to those results, in our study, the G145R mutation was
heavily underrepresented (2.07%), from which it can be in-
ferred that the genotype B, C and D strains in Northwest
China may have less likelihood of vaccine escape [20].
Furthermore, compared to the G145R mutation, several
mutations within the major hydrophilic region were de-
tected at high prevalence, such as M134Y and S143T/L.
It can be inferred that these mutations may have been
strongly selected in long-term infected carriers, in
whom a strong antibody response develops [21].
This study has several limitations. First, the analysis
was restricted to HBsAg-positive infections as detected
by current blood HBV-screening assays. Consequently,
infections by highly divergent variants that would not be
detected by these assays would not be identified. Second,
cases with low HBV qualification were not selected for
complete HBV genome amplification by PCR due to amp-
lification and sequencing accuracy, and moreover, a mod-
erate proportion of cases were not able to be characterized
due to failure of complete genome amplification by PCR.
Third, bulk PCR product sequencing was performed in
this study and therefore may not have detected cases of
dual infection, minor populations of drug resistance or
immune escape variants represented in viral quasi-
species.
Conclusions
In summary, the role of genotype D strains in HBV
prevalence should not be ignored in Northwest China.
Based on B, C and D genotype consensus sequences,genotype-dependent variability was frequently observed,
and this variability might modulate hepatitis B-related
clinical treatments and host antibody development.
Among all detected clinically relevant mutations, the
prevalence of confirmed vaccine-escaping mutations
was low, and no HBV antiviral drug resistance muta-
tions were observed.
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